Clinical Trials Directory

Trials / Conditions / Hormone Sensitive Prostate Cancer

Hormone Sensitive Prostate Cancer

16 registered clinical trials studyying Hormone Sensitive Prostate Cancer — 5 currently recruiting.

StatusTrialSponsorPhase
RecruitingThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enza
NCT07028853
PfizerPhase 3
Active Not RecruitingComeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
NCT06463457
Atish Choudhury, MDPhase 2
RecruitingPSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
NCT06392295
University of MiamiPhase 2
Active Not RecruitingPSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
NCT06479187
Brigham and Women's HospitalPhase 4
Active Not Recruiting[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cance
NCT06229366
Eli Lilly and CompanyPhase 1
RecruitingComparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
NCT05983783
The First Affiliated Hospital with Nanjing Medical UniversityPhase 3
RecruitingMetastasis-directed Therapy for Oligorecurrent Prostate Cancer
NCT05352178
Universitaire Ziekenhuizen KU LeuvenPhase 3
Active Not RecruitingEffect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients
NCT06193993
National University Hospital, SingaporePhase 1
CompletedA Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer
NCT04995042
Jiangsu HengRui Medicine Co., Ltd.Phase 1
Active Not RecruitingAndrogen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
NCT04335682
Alliance Foundation Trials, LLC.Phase 2
Active Not RecruitingCapivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN
NCT04493853
AstraZenecaPhase 3
Active Not RecruitingNivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
NCT04126070
Xiao X. Wei, MDPhase 2
UnknownCardiovascular Events in GnRH Agonist vs. Antagonist
NCT04182594
Rabin Medical CenterPhase 2
UnknownNeoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer
NCT04220398
RenJi HospitalN/A
RecruitingEvaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Ra
NCT06473259
Santa Chiara Hospital—
Active Not RecruitingSafety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBA
NCT02319837
PfizerPhase 3